The HFSA Virtual Board Certification Review 2021 will be comprised of renowned heart failure experts presenting curriculum that has been tailored to the actual ABIM examination blueprint. The course will take place over three (3) days (July 16-18, 2021) and include the components outlined below. Check back soon for preliminary agenda, Advance Program, and more!
Download the Advance Program >>
The program will be made up of the following components to allow attendees greater access to the content.
This pre-recorded, ondemand webinar series features the basics and can be completed at the attendee's convenience. Coming soon!
A three day virtual meeting (July 16-18, 2021) delivered by top experts in the field. Sessions will be available to download within 48 hours of the session date. Coming soon!
Post-meeting, virtual livestream Q&A panel taking place on Friday, October 1, from 4:00 PM - 5:00 PM ET to allow attendees to ask follow-up questions.
The HFSA Virtual Board Certification Review 2021 is designed for physicians who are preparing to take the ABIM Advanced Heart Failure & Transplant Cardiology Maintenance of Certification Exam or heart failure specialists seeking an in-depth review in heart failure.
Upon completion of the activity, participants will demonstrate improved competence and ability to:
For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:
- Identify gaps in knowledge about advanced heart failure and transplant cardiology
- Focus study efforts on filling identified knowledge gaps
- Practice for the certification examination with ABIM-style multiple-choice test questions
For Clinical Practice:
- Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
- Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
- Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
- Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
- Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
- Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
- Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
- Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device
Concise presentations by national experts will focus on blueprint content.
Each webinar is 30 minutes in length. This series is available to all registered attendees in the online meeting platform under the OnDemand tab to be completed at the attendee's convenience.
Title |
Speaker |
---|---|
Heart Failure Epidemiology and Risk Factors | Sadiya Kahn |
Pathophysiology I: Cellular and Energetic Considerations | Daniel Burkhoff |
Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations | Daniel Burkhoff |
Diagnosis and Clinical Assessment | Mark Drazner |
Cardio-Oncology for the HF Boards | Bonnie Ky |
Clinico-Pathologic Correlates in HF / Images for the HF Boards | Jon Lomasney |
Statistics for the HF Boards | Brian Claggett |
The virtual meeting dates will take place July 16-18. Attendees should anticipate being online for the full sessions to maximize their learning potential. To attend a session on a virtual meeting day, click on the “Sessions” tab in the online platform.
If a participant is unable to participate live, the ondemand recordings of the sessions will be available within 48 hours of the session date on the “OnDemand” tab of the online platform.
Scroll down to see the full agenda, and look below for the basic outline on days and topics.
All sessions below are listed in Eastern Standard Time.
Date |
Livestream Times |
Topics |
---|---|---|
Day #1 | Friday, July 16 |
3:00 PM – 6:20 PM EST |
|
Day #2 | Saturday, July 17 | 11:00 AM – 8:00 PM EST |
|
Day #3 | Sunday, July 18 | 11:00 AM – 5:30PM EST |
|
A post-meeting, virtual livestream Q&A panel to allow attendees to ask last-minute questions prior to the examination will take place Friday, October 1, 2021 from 4:00 PM - 5:00 PM ET. Faculty "Office Hours" will be live; therefore, attendees are encouraged to be available during these hours to engage in Q&A as final prep for the exam. More information coming soon.
In addition to the core program components, attendees will have access to the following:
- A question bank - updated for 2021!
- Recommended reading list
- Live polling, Q&A, and chat features available during the livestream days
- Chat with fellow attendees and faculty throughout the course of the meeting
The question bank and recommended reading list will be available in the "Attendee Resources" tab of the online platform.
Program Agenda
All sessions are listed in Eastern Standard Time.
Welcome and HFSA Introduction
Akshay Desai
John Barnes, HFSA CEO
Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies
Nancy Sweitzer
Immunology: The Basics, PRA, Sensitization, Crossmatch
Sean Pinney
Rejection: Cellular and Antibody Mediated
Sean Pinney
Managing Immunosuppression and Drugs
Michelle Kittleson
Heart Transplant, Clinical Outcomes and Complications
Michelle Kittleson
Q&A Panel I
Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer
Welcome and Introductions
Akshay Desai
Hemodynamics in HF I
James Fang
Hemodynamics in HF II
James Fang
Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)
Clyde Yancy
Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)
Mark Drazner
Break
HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)
Sanjiv Shah
Pulmonary Hypertension
Jonathan Rich
Management of Common Arrhythmias I - Atrial Fib and Flutter
Roderick Tung
Management of Common Arrhythmias in HF II
Roderick Tung
Device Therapy in Heart Failure I - Sudden Death Prevention
Wendy Tzou
Device Therapy in Heart Failure II - CRT
Wendy Tzou
Break
Management of the Hospitalized HF Patient
Maria Rosa Costanzo
Cardio Renal Failure Interactions in Heart Failure
Jeff Testani
Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)
Akshay Desai
Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)
Jane Wilcox
Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)
Sanjiv Shah
Q&A Panel II
Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer
Welcome and Introductions
Akshay Desai
Cardiogenic Shock Management
Nancy Sweitzer
MCS I: Durable MCS Devices and Outcomes
Joseph Rogers
MCS II: Temporary Support Devices and ECMO for the Boards
Jennifer Cowger
MCS III: MCS Complications and Patient Management
Jennifer Cowger
MCS IV: Interactive Shock and Device Management
Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer
Break
Assessment of Functional Capacity including cardiopulmonary exercise testing
Gregory Lewis
Adult Congenital Heart Disease for the HF Specialist
Eric Krieger
Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)
Akshay Desai
Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)
Jane Wilcox
Management of Comorbidities in Heart Failure - Diabetes, Sleep Disorders, Iron Deficiency/Anemia, COPD
Maria Rosa Costanzo
Q&A Panel III
Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer